NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

CompletedN/A

Sponsor: AstraZeneca

Conditions: Chronic Kidney Disease

Countries: Spain

This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD)

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Meets CKD definition criteria: having at least two eGFR measures ≤60 ml/min/1.73m2 measured ≥90 to 730 days apart and/or UACR ≥ 30 mg/g, and/or at least one measurement indicative of proteinuria (or with proteinuria ERA-ICD code) or CKD code.
* Age ≥18 years.
* 12 months continuous enrolment in the data base prior to index
* 12 months continuous enrolment in the data base after index date.

Exclusion Criteria:

* T1DM on or before index date.
* Diagnosis of gestational diabetes mellitus on or before index date

Locations (1)

Madrid, Spain